Abstract: For the past few years, regulatory bodies, industry advocacy groups, and private companies have been tackling the concept of incorporating risk into the design of clinical trials and customizing monitoring strategies based on those risks to achieve higher-quality outcomes. Regulatory guidance like ICH, and FDA encourage sponsors to adopt advanced concepts of monitoring in… Continue reading Revolutionizing Clinical Trial Monitoring: The Power of Risk-Based Monitoring (RBM)